The survival analysis of patients with Paget’s disease and underlying invasive breast carcinoma

凌　泓; 徐晓丽

doi:10.19401/j.cnki.1007-3639.2017.08.009

您当前的位置：

首页 >

文章列表页 >

The survival analysis of patients with Paget’s disease and underlying invasive breast carcinoma

更新时间：2025-12-31

- The survival analysis of patients with Paget’s disease and underlying invasive breast carcinoma
- China Oncology Vol. 27, Issue 8, Pages: 655-660(2017)
- 作者机构：
  
  1. 复旦大学附属肿瘤医院乳腺外科，复旦大学上海医学院肿瘤学系,上海,200032
  2. 复旦大学附属肿瘤医院病理科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2017.08.009
  CLC：
- Published Online：21 September 2017，
  
  Published：21 September 2017
- 稿件说明：
移动端阅览
凌　泓,徐晓丽. 乳房派杰氏病合并浸润性乳腺癌患者的生存分析[J]. 中国癌症杂志, 2017, 27(8): 655-660.

凌　泓, 徐晓丽. The survival analysis of patients with Paget’s disease and underlying invasive breast carcinoma[J]. China Oncology, 2017, 27(8): 655-660.
凌　泓,徐晓丽. 乳房派杰氏病合并浸润性乳腺癌患者的生存分析[J]. 中国癌症杂志, 2017, 27(8): 655-660. DOI： 10.19401/j.cnki.1007-3639.2017.08.009.

凌　泓, 徐晓丽. The survival analysis of patients with Paget’s disease and underlying invasive breast carcinoma[J]. China Oncology, 2017, 27(8): 655-660. DOI： 10.19401/j.cnki.1007-3639.2017.08.009.

摘要

背景与目的：乳房派杰氏病(Paget’s disease)是一种很罕见的疾病。文献报道该病患者的生存情况与其下乳房内的病灶的恶性程度相关。该研究旨在探索合并浸润性乳腺癌的乳房派杰氏病的临床病理特征并分析患者的生存率。方法：2002—2007年，共54例在复旦大学附属肿瘤医院接受治疗的合并浸润性乳腺癌的乳房派杰氏病患者纳入该研究。由于乳腺派杰氏病大多数为人表皮生长因子受体2(human epidermal growth factor receptor 2，HER-2)阳性，研究者随机收集了同期72例HER-2阳性浸润性乳腺癌患者作为对照组，比较两组的生存差异。结果：25例(46.3%)研究组患者没有典型的乳头乳晕派杰氏病皮肤表现，35例(64.8%)研究组患者浸润性癌灶超过2 cm，26例(48.1%)研究组患者腋窝淋巴结有转移。与对照组的患者相比，派杰氏病患者的复发事件更多(5年无复发生存率：76.4% vs 48.5%，P0.01)。对照组复发事件多集中于术后3年内，而派杰氏患者复发风险在术后5年内持续存在。研究组的5年总生存率(61.0%)也低于对照组(80.6%，P=0.01)。结论：合并浸润性癌的乳房派杰氏病患者比HER-2阳性乳腺癌患者的预后差。

Abstract

Background and purpose: Paget’s disease (PD) of the breast is a rare disease. The survival of PD was reported to be related to the characteristics of the underlying carcinoma. This study aimed to investigate the characteristics and survival of PD patients with underlying invasive breast carcinoma (IBC). Methods: Fifty-four patients diagnosed with PD and an associated IBC in Fudan University Shanghai Cancer Center from 2002 to 2007 were recruited in this study as study group. Since most PD overexpress HER-2

72 patients with HER-2-overexpressing breast cancer were randomly recruited as control group. This study compared survival between these two groups. Results: Twenty-five (46.3%) patients in study group had no clinical manifestation of PD and were diagnosed unexpectedly by a histologic examination. Thirty-five (64.8%) patients in study group had tumors larger than 2 cm

twenty-six(48.1%) patients in study group had chance of axillary lymph node involvement. Compared with control group

patients in study group tended to have more events (5-year relapse-free survival: 76.4% vs 48.5%

P0.01). In the control group

most events occurred in the first 3 years after operation

while recurrence might happen all along in the 5 years after operation in study group. Patients in study group also had a poorer overall survival than in control group (61.0% vs 80.6%

P=0.01). Conclusion: Patients with Paget’s disease and underlying invasive breast cancer tend to have poorer survival than those with HER-2-overexpressing breast cancer.

关键词

Keywords

references

Views

3167

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Impact of radiation-induced lymphopenia on prognosis in patients with limited-stage small cell lung cancer: a cohort study

Impact of tumor diameter on post-radiofrequency ablation survival and local progression risk in patients with colorectal cancer lung metastasis

Research on high-throughput detection of plasma cell-free DNA for targeted therapy-related genes screening and prognosis prediction in non-small cell lung cancer patients

Prognostic factor analysis of surgical treatment for cerebellar metastases in 36 patients

Distribution of metastatic sites and survival analysis of patients with non-metastatic lung cancer at initial diagnosis based on hospital registration

Related Author

Xingwen FAN

Kailiang WU

Yulei PEI

Yaqi LI

Yihua WANG

Leilei YING

Kening LI

Chao CHEN

Related Institution

Department of Thoracic Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Department of Oncology, Taiyuan Central Hospital/The Ninth Clinical Medical College of Shanxi Medical University

Department of Interventional Therapy, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Molecular Diagnostics, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine

BSL-3 Laboratory(Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University

AI问答

⁰